TCS Industries Limited (China-sourced API supplier) supplies Mitomycin C — API CAS 50-07-7 for pharmaceutical B2B procurement — COA, MSDS, and technical documentation available on request.
> Overview
| Product Name | Mitomycin C |
|---|---|
| Structural Formula |  |
| CAS Number | 50-07-7 |
| Molecular Formula | C15H18N4O5 |
| Molecular Weight | 334.33 g/mol |
| InChIKey | NWIBSHFKIJFRCO-WUDYKRTCSA-N |
| SMILES | Available on request where applicable |
| Appearance | Blue-violet crystalline powder |
| Purity / Grade | By agreed specification and batch COA |
| Storage | Store at controlled room temperature, protect from light |
Mitomycin C (CAS 50-07-7) is a cytotoxic antibiotic isolated from Streptomyces caespitosus with the formula C₁₅H₁₈N₄O₅ (MW 334.33). It functions as a bioreductive alkylating agent, forming DNA cross-links after enzymatic reduction of its quinone moiety. Mitomycin C is used for bladder cancer intravesical therapy, gastric cancer, and ophthalmic surgery adjunct, and is on the WHO Model List of Essential Medicines.
TCS Industries Limited, a Hong Kong-based trading and sourcing company, supplies Mitomycin C API in pharmaceutical grade for global procurement programs.
> Applications
Intravesical therapy for bladder cancer
Mitomycin C 20–40 mg in saline is instilled into the bladder immediately after transurethral resection of bladder tumor (TURBT) to reduce recurrence of non-muscle-invasive bladder cancer (NMIBC). The direct mucosal contact achieves high local drug concentration with minimal systemic absorption. Sylvester et al. (Eur Urol, 2004, 46:147–154) demonstrated in a meta-analysis that single immediate postoperative intravesical mitomycin C instillation reduced bladder cancer recurrence by 39% compared to TURBT alone.
Ophthalmic and oncology applications
Mitomycin C (0.02–0.04%) is applied topically during pterygium and glaucoma filtering surgery to prevent fibrosis and scarring. In systemic oncology, it is used IV in combination regimens for gastric, pancreatic, and anal cancers. Topical application in nasal and laryngeal surgery prevents stenosis.
> Sourcing & Supply
TCS Industries Limited supports development, qualification and commercial purchasing discussions for Mitomycin C with buyers in Australia, New Zealand, Canada and South Korea.
- Evaluation and commercial quantities: 5 g samples for analytical qualification; 50 g and 500 g for production. Fermentation-derived pharmaceutical-grade powder. Cytotoxic API — dedicated containment required. DMF reference letters available.
- Pallet quantities and production campaigns: repeat supply is coordinated against packaging, lead time, annual demand and destination-market import requirements.
> Quality & Documentation
Key specification parameters include assay (≥97.0%), related substances (7-N-aminomitosene, porfiromycin), loss on drying, residual solvents, heavy metals, and microbial limits. Blue-violet crystalline powder. Soluble in water, methanol, and acetone. Light-sensitive and thermally unstable in solution. Handle as cytotoxic material. Identity by HPLC, UV-Vis (λmax 360 nm), and IR. Meets USP (Mitomycin) and JP. COA and MSDS are standard.
> Packaging
Mitomycin C is a blue-violet crystalline powder, cytotoxic. Light-sensitive — store protected from light. Standard packaging includes amber glass vials or double-sealed foil bags under nitrogen (5 g, 10 g, 50 g, or 100 g). Store at controlled room temperature (15–25 °C) or 2–8 °C. Cytotoxic substance labeling applies. Shelf life is typically 24 months. Labels and documents are checked before dispatch.
> Pricing & MOQ
Pricing is quoted by specification, packaging and destination. Common commercial discussions use 25 kg bag/drum formats, pallet quantities and production-campaign planning; smaller samples may be reviewed for qualified formulation teams.
> Regulatory & Compounding Context
Mitomycin is monographed in USP and JP. FDA-approved (Mutamycin, 1974; Jelmyto for urothelial carcinoma, 2020). EMA-authorized. On the WHO Model List of Essential Medicines. Generic mitomycin for injection approved. Manufacturing requires cytotoxic API handling and fermentation capabilities. DMF support available.
> Alias Index
- INN: Mitomycin
- CAS Number: 50-07-7
- Formula: C₁₅H₁₈N₄O₅ (MW 334.33)
- Brand names: Mutamycin, Jelmyto (intravesical gel)
- ATC code: L01DC03
- Source: Streptomyces caespitosus fermentation
- Commercial request terms: mitomycin C API, MMC bulk, bladder cancer API, intravesical mitomycin, TCS Industries Limited
> FAQ
Why is Mitomycin called a bioreductive alkylating agent?
Mitomycin C requires enzymatic reduction of its quinone group to become an active alkylating agent. This reduction occurs preferentially in hypoxic (low oxygen) tumor environments, providing some tumor selectivity. The activated form generates bis-alkylating species that cross-link DNA at N²-guanine positions, inhibiting DNA replication.
What documents are available for Mitomycin C orders?
COA and MSDS are standard for commercial discussions. COO, packing list, invoice and other import-support documents can be arranged according to order scope.
Do you supply Mitomycin C to Australia and Canada?
Yes. We support B2B buyers in Australia, New Zealand, Canada and South Korea, subject to route and document review.
Do you supply New Zealand and South Korea?
Yes. We review Australia, New Zealand, Canada and South Korea for project supply, import documents, packaging and logistics planning before quotation.
How is intravesical therapy administered?
Mitomycin C 20–40 mg is dissolved in 20–40 mL saline and instilled into the emptied bladder via urethral catheter. The patient retains the solution for 1–2 hours, then voids. Single immediate instillation after TURBT is standard; maintenance instillation schedules (weekly for 6–8 weeks) are used in intermediate-risk NMIBC.
Why is Mitomycin used in eye surgery?
Mitomycin C (0.02–0.04% solution) applied for 1–5 minutes during glaucoma trabeculectomy or pterygium excision inhibits fibroblast proliferation and prevents postoperative scarring, which would cause surgical failure. This is an off-label but universally accepted ophthalmologic application. The solution is freshly prepared from powder at the time of surgery.
Can you arrange samples before commercial purchasing?
Samples or evaluation quantities may be reviewed for qualified buyers after target specification, application and destination-market requirements are clarified.
How is Mitomycin C packaged for export?
Packaging is confirmed by quantity and material properties. Typical options include foil bags, HDPE containers, fibre drums, 25 kg bags or palletized export packaging.
Can buyer-defined specifications be reviewed?
Yes. Send the specification, methods, impurity limits and required documents. TCS can review feasibility before confirming quotation and lead time.
What payment terms are normally used?
Standard payment is 100% T/T before dispatch unless a different arrangement has been approved for an established commercial account.
What lead time should buyers expect?
Lead time depends on stock, batch size, document scope and destination. Available stock can move faster; made-to-order or pallet programs require longer planning.
What cytotoxic handling is required?
Mitomycin C is a genotoxic cytotoxin requiring OEB 4/5 containment during manufacturing and formulation. Personnel must use appropriate PPE. Closed-system drug transfer devices (CSTDs) are recommended for clinical preparation. Environmental monitoring and cytotoxic waste disposal procedures must be followed.
Last reviewed: June 2026
Evaluation and research orders (≤10 kg) are shipped with COA, MSDS, and certificate of origin. Bulk commercial orders (>10 kg) qualify for volume pricing with a full technical documentation package available on request.
> Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.